CareLit Fachartikel
Subsequent Malignant Neoplasms in Survivors of Pediatric DAL/GPOH-Hodgkin-Lymphoma Trials
W Dörffel, M Riepenhausen, H Lüders, J Brämswig, G Schellong · Klinische Pädiatrie · 2014 · Heft 03
Dokument
1200278
CareLit-ID
Jahr
2014
Publikation
PDF
nein
Metadaten
DOI
ja
zitierfähig
Bibliografische Angaben
Zusammenfassung
Question: Subsequent malignant neoplasms (SMN) represent one of the most serious late effects following treatment of pediatric Hodgkin lymphoma (HL). Their evaluation is essential for final assessment of therapy optimization trials. Methods: 2548 patients from Germany, Austria and Switzerland were treated in 7 consecutive DAL/GPOH-HL trials between 1978 and 2002, the majority with combined modality treatment including chemo- and radiotherapy. We obtained information about late effects including SMN from patients and/or their physicians every 2 or 3 years. We documented the different diagnoses of SMN and evaluate…
Schlagworte
After
Physicians
Diagnosis
Germany
Breast
Klinische Pädiatrie
